{"name":"Mediar Therapeutics","slug":"mediar-therapeutics","ticker":"","exchange":"","domain":"mediar.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNSkh0d2tPSnlKVHRHRjZxLVdvb2RrQkxMNS1nclRsVTAtbHVUX0xmTDRUdlo4RWNuM2tCWmRuWFprdUs0ZXFCeGhVRXJsLVNNcU1HaDlxQVJOd2F6eFRqbVRITU1rWHhDWGhiVlZoUndwR3V5cTNTTy1nMmtPSmpSQ21aNTZzQ3dVOUhsLU5udjR4QmoybFJRaGZLbE9Qc3dOaVNjX1psRzQxd20yWDRKRG84eDU?oc=5","date":"2026-04-07","type":"pipeline","source":"Kalkine Media","summary":"ANI Pharmaceuticals (NASDAQ:ANIP) Price Gap Sparks Nasdaq Futures Focus - Kalkine Media","headline":"ANI Pharmaceuticals (NASDAQ:ANIP) Price Gap Sparks Nasdaq Futures Focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNYnprWGlxNHNyaXA1WlI3eDc2SUdLV3ZZR21OeVlwWW9jSTdtdUR0M1hITXh2OXkzRnpYN2doU1haakI1SFh3OTBHYS1FWUdXa0xOMEppX3B2aXc5SnFBZmxWaE5oQU8tOEpxTktvSkdUOTFXTVk1aWx4ME5xbjBVV090OTRpTnZwMmpUZ1JmNldoVlJvVFRWMDhia3NDendlQkxRQnpESnM5YnRady1fT2xEaFZIdEE?oc=5","date":"2026-04-01","type":"pipeline","source":"Bayer","summary":"Bayer’s strongest-ever pharma portfolio and promising pipeline drive future growth - Bayer","headline":"Bayer’s strongest-ever pharma portfolio and promising pipeline drive future growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQbDJDTDU3X2NsS2NIQ282U2xhVHVCU19RbjVOWkhxUUJ5MUFvNHlLSzcweDBvOXYxN0xQZWRuZl9wa1E2R1BQN1lGQ3VZV1puYy1ka0E2NlgwYW1vWmJDS3pEVHQ0dm5NUnJPTVJHZl9ST3l5SHVLY0VpWUpCakhkbERCdFM3TkE4MVBzRXVnRDZEdzIxTE02Uml2RUtkYlhLaTlwZEpPaE9QYW9NajNObkNXeGlUS05yc29aQl81eVVfeTlsQWpfSk5ZMjhwa2RoM3h2Z1dFNGlOcGpCRld0ZmFB?oc=5","date":"2026-03-30","type":"deal","source":"BioSpace","summary":"IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness - BioSpace","headline":"IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNVHVPcjJiLVljS3pRaEhXdlRwMWRLQlpxZFd6NFNNQmJIVW53RDljaFUwR1RXWmtpbjlLOWJUaUdaMWZ0THk1UDZHVF9EdkF1QlRzT0V4Q0htQkY4V1ZwM19hSFlNUXpUOTRfVS1aTHN2MEdBNHl1UU1HUzR3eXcyblZYNTkzTlhGNWsxcVFwN2UzanlCN3A0?oc=5","date":"2026-03-23","type":"pipeline","source":"Traders Union","summary":"Applied Therapeutics shifts social media operations to Cycle Pharmaceuticals - Traders Union","headline":"Applied Therapeutics shifts social media operations to Cycle Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQMjEweFdRbFo3YjQzcjd4NnB2LWZqWm53MXl2OVlWWXpzTm0wY0wxa2VOdjY1S2QyUEExaEkxcG41RjJfOUFNanFRVlRvcnZ6NFN1QnR2cmpJZkFmc2VsRFRKR3c2VkNIY0Z2R3J4NG1PVFlTMlZWZ3VlS1JxanlmbTZRU0h2R2h1ZWE0UnlvRGF5aEM5akdoUXA2Y0l3WXhUVjJFbXk0Tjd3R25NbkJkV2I2el9jUQ?oc=5","date":"2026-01-30","type":"deal","source":"AstraZeneca","summary":"AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals - AstraZeneca","headline":"AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxQdVRobENZdEoyc01yTWRwZFF2X3Jxd2VPS21kaDNDa3ZBam5wQXNIVTBsR015bEFMU1hkVGN6ekd1UmlVYUJtR3RkNmFYb3R6SC1XanFjSUY3dW5QRUhLT2pPVzBkWHBzX19wZk5SWTZ1VjBTNm1XT2xxX3YtaDNGdTlNQjZteEVMTWlaRUJkdEJ5bjloaGhNWlFHUkVveUw4RktTX0NtZXZLMjRHQUFJZWdaRThfZmZ0REFmUkZYVzRfd21OSE9YeGNIOWtPajdvQ19RYjZPM3lNalVBMUdmU3NUcFlMYVhZaVBZdzlfYk80ZUhwaEpUblNfUldibmN6SzdDN3hoTVNkNmlFU1dqRE9XUVU5YVZUaUg3bA?oc=5","date":"2026-01-07","type":"pipeline","source":"PR Newswire","summary":"Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio - PR Newswire","headline":"Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class F","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE01b2pLTXRRRjJDWEdwU1dCZ3AzaHpDT2VzOUt5TDlpeUI3UUEzOFV5OGNlN3hFeUV3Qy1Yb3UyemdaNDdnQ2dmRGJIcnRlVTlwbEkw?oc=5","date":"2026-01-07","type":"pipeline","source":"FirstWord Pharma","summary":"Biopharma bites: Corsera, Mediar, Rakuten and Spiro lead wave of financings - FirstWord Pharma","headline":"Biopharma bites: Corsera, Mediar, Rakuten and Spiro lead wave of financings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQUkVPV3E1eWh0ekxxbENpNEhlMDRPUFBKbnRLMlpaSXNISFpyQzJwMlBkQWRFM0liRGo2QzRMcENGa0RuMmNkSFI5akNTQUQwU3hrSW85RzA0Zm1sRUJFYVVYVHVDOVhUUFQ4a2xTSGRFeFp2a19kdnlLVUZVZExyNVBveXJoVjBUYkg1X0ZmMlRuOHZDanhvUUF4dndxdW9Gbnp6cHBZakpIMnpSWC10WlVsLXc4dEpNcFZsSjRKWGFQOWdnUi14TQ?oc=5","date":"2026-01-07","type":"deal","source":"reuters.com","summary":"AbbVie denies media reports of talks to buy Revolution Medicines - reuters.com","headline":"AbbVie denies media reports of talks to buy Revolution Medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQUklDSldubVVxVjFZQkRGcmxIYzZrRW1PdVd0LUlUUkRsMkotUHRBRUVPUXdLc2Vxb1hmbndNTXhOam9Eei0yb08xMGpHYU9tRWlxaFJQYW4wcjUxUnZVdjVIRy1UYVUwcXlWcjFIdHVHemRscE0yZnVaVU1nWEU0aXFYZnVZX2xLT1VNN1licWppZ0oyOWE2NXAwNllBQXBwMVV1N3ctYXBJOFBqYkg5OUxOejRXcG1tY1FqUy05ZkE0cmp4clBrTFZHLV9ZZFlQbXFEVUJ3c3V5MENDVXNJemsxTFJwajNRSHFyTW8zaHBCRTVwbUJmS1dR?oc=5","date":"2025-10-26","type":"deal","source":"Novartis","summary":"Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline - Novartis","headline":"Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscie","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE9zbTdNenZlbG1xZFFxcnVkclEwN0tOVUpmSUxkcVdrSjNHclNDSnUwZnFpWHdxQ0Y4czFHMXc1SGRPdFBQX1VrYXozdGdRSGxqanJGMlBXWDV1LWVBYUVPT0VSUmlxcjVXWGtEN1g3RXhUUF9QckgtdQ?oc=5","date":"2025-01-13","type":"deal","source":"Pharmaceutical Technology","summary":"Mediar Therapeutics signs licensing deal with Eli Lilly for IPF treatment - Pharmaceutical Technology","headline":"Mediar Therapeutics signs licensing deal with Eli Lilly for IPF treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPd3M3bXdPX0FOZmNCWTN6bE45RTJpRnFkR042dzlEc0NPMWZKNURIX1FEUF9hYlFZNFk5M3F0TXRzU1V3bGJ5ZXhyUVZLdUJlNGw3NGVVM09DT3YxS3haWDhOczNMZVN2eFhzd0haZ1VXcjg5M2ZKaF9pTjBzZndjTEM3TTJhNnpnMy1vTV9yM3E5T3F4a0JLcDRQU3lmU2Z6TlBIam91LWVlbnM?oc=5","date":"2023-03-15","type":"pipeline","source":"Fierce Biotech","summary":"Armed with $105M and Big Pharma backing, Mediar takes aim at fibrotic mediators - Fierce Biotech","headline":"Armed with $105M and Big Pharma backing, Mediar takes aim at fibrotic mediators","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNUmNpRHVxdVBXb2JkRW1Vc3JCNDZQb1BMVHRTSnZnenVkYWxjQjhIU1JiY1VFc1daa0t2OUd3XzhKNnJLYzNiN0VCT1ZGVnJoNmJnX3ktSXdJTlBxVTNxc0VkRjAzRTBpVkN6YkE1eHVRSkJSRktCTU1DUEJVeldPLWdGejhBU0tUU3R3alhOc3NIenNE?oc=5","date":"2023-03-15","type":"pipeline","source":"BioPharma Dive","summary":"With focus on fibrosis, startup Mediar draws big pharma backing - BioPharma Dive","headline":"With focus on fibrosis, startup Mediar draws big pharma backing","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}